Page 19 - 中国全科医学2022-05

·528· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

［8］ATHERTON J J，SINDONE A，DE PASQUALE C G，et al. ejection fraction［J］. Eur J Heart Fail，2017，19（12）：1624-
National Heart Foundation of Australia and Cardiac Society of 1634. DOI：10.1002/ejhf.945.
Australia and New Zealand：Australian clinical guidelines for the ［19］LAM C S P，GAMBLE G D，LING L H，et al. Mortality associated
management of heart failure 2018［J］. Med J Aust，2018，209（8）： with heart failure with preserved vs. reduced ejection fraction in a
363-369. DOI：10.5694/mja18.00647. prospective international multi-ethnic cohort study［J］. Eur Heart J，
［9］VIRANI S S，ALONSO A，APARICIO H J，et al. Heart disease 2018，39（20）：1770-1780. DOI：10.1093/eurheartj/ehy005.
and stroke statistics-2021 update：a report from the American heart ［20］CLELAND J G F，BUNTING K V，FLATHER M D，et al. Beta-
association［J］. Circulation，2021，143（8）：e254-743. DOI： blockers for heart failure with reduced，mid-range，and preserved
10.1161/CIR.0000000000000950. ejection fraction：an individual patient-level analysis of double-
［10］GERHARD-HERMAN M D，GORNIK H L，BARRETT C，et al. blind randomized trials［J］. Eur Heart J，2018，39（1）：26-
2016 AHA/ACC guideline on the management of patients with lower 35. DOI：10.1093/eurheartj/ehx564.
extremity peripheral artery disease：executive summary：a report of ［21］RASTOGI A，NOVAK E，PLATTS A E，et al. Epidemiology，
the American college of cardiology/American heart association task pathophysiology and clinical outcomes for heart failure patients with
force on clinical practice guidelines［J］. Circulation，2017，135（12）： a mid-range ejection fraction［J］. Eur J Heart Fail，2017，19（12）：
e686-725. DOI：10.1161/CIR.0000000000000470. 1597-1605. DOI：10.1002/ejhf.879.
［11］TSUJI K，SAKATA Y，NOCHIOKA K，et al. Characterization ［22］BRANN A，JANVANISHSTAPORN S，GREENBERG B.
of heart failure patients with mid-range left ventricular ejection Association of prior left ventricular ejection fraction with clinical
fraction-a report from the CHART-2 Study［J］. Eur J Heart Fail， outcomes in patients with heart failure with midrange ejection
2017，19（10）：1258-1269. DOI：10.1002/ejhf.807. fraction［J］. JAMA Cardiol，2020，5（9）：1027-1035. DOI：
［12］IBRAHIM N E，SONG Y，CANNON C P，et al. Heart failure with 10.1001/jamacardio.2020.2081.
mid-range ejection fraction：characterization of patients from the ［23］PFISTERER M，BUSER P，RICKLI H，et al. BNP-guided vs
PINNACLE Registry®［J］. ESC Heart Fail，2019，6（4）： symptom-guided heart failure therapy：the Trial of Intensified vs
784-792. DOI：10.1002/ehf2.12455. Standard Medical Therapy in Elderly Patients With Congestive Heart
［13］王华，李莹莹，柴坷，等 . 中国住院心力衰竭患者流行病学及 Failure （TIME-CHF） randomized trial［J］. JAMA，2009，301（4）：
治疗现状［J］. 中华心血管病杂志，2019，47（11）：865- 383-392. DOI：10.1001/jama.2009.2.
874. DOI：10.3760/cma.j.issn.0253-3758.2019.11.004. ［24］CONNOR C M，STARLING R C，HERNANDEZ A F，et al.
WANG H，LI Y Y，CHAI K，et al. Contemporary epidemiology and Effect of nesiritide in patients with acute decompensated heart
treatment of hospitalized heart failure patients in real clinical practice failure［J］. N Engl J Med，2011，365（1）：32-43. DOI：
in China［J］. Chin J Cardiol，2019，47（11）：865-874. DOI： 10.1056/nejmoa1100171.
10.3760/cma.j.issn.0253-3758.2019.11.004. ［25］TROMP J，KHAN M A，KLIP I T，et al. Biomarker profiles
［14］ZHANG Y H，ZHANG J，BUTLER J，et al. Contemporary in heart failure patients with preserved and reduced ejection
epidemiology，management，and outcomes of patients hospitalized fraction［J］. Journal of the American Heart Association，2017，6
for heart failure in China：results from the China heart failure （4）：A991.
（China-HF） registry［J］. J Card Fail，2017，23（12）： ［26］TROMP J，WESTENBRINK B D，OUWERKERK W，et al.
868-875. DOI：10.1016/j.cardfail.2017.09.014. Identifying pathophysiological mechanisms in heart failure with
［15］FONAROW G C，STOUGH W G，ABRAHAM W T，et al. reduced versus preserved ejection fraction［J］. J Am Coll Cardiol，
Characteristics，treatments，and outcomes of patients with 2018，72（10）：1081-1090. DOI：10.1016/j.jacc.2018.06.050.
preserved systolic function hospitalized for heart failure：a report ［27］VAN WOERDEN G，GORTER T M，WESTENBRINK B D，et al.
from the OPTIMIZE-HF Registry［J］. J Am Coll Cardiol，2007， Epicardial fat in heart failure patients with mid-range and preserved
50（8）：768-777. DOI：10.1016/j.jacc.2007.04.064. ejection fraction［J］. Eur J Heart Fail，2018，20（11）：1559-
［16］SHAH K S，XU H L，MATSOUAKA R A，et al. Heart failure 1566. DOI：10.1002/ejhf.1283.
with preserved，borderline，and reduced ejection fraction：5-year ［28］HJALMARSON A，GOLDSTEIN S，FAGERBERG B，
outcomes［J］. J Am Coll Cardiol，2017，70（20）：2476- et al. Effects of controlled-release metoprolol on total mortality，
2486. DOI：10.1016/j.jacc.2017.08.074. hospitalizations，and well-being in patients with heart failure：the
［17］IBRAHIM N E，SONG Y，CANNON C P，et al. Heart failure with Metoprolol CR/XL Randomized Intervention Trial in congestive heart
mid-range ejection fraction：characterization of patients from the failure （MERIT-HF）. MERIT-HF Study Group［J］. JAMA，
PINNACLE Registry®［J］. ESC Heart Fail，2019，6（4）： 2000，283（10）：1295-1302. DOI：10.1001/jama.283.10.1295.
784-792. DOI：10.1002/ehf2.12455. ［29］JIMENEZ-MARRERO S，MOLINER P，RODRÍGUEZ-
［18］KOH A S，TAY W T，TENG T H K，et al. A comprehensive COSTOYA I，et al. Sympathetic activation and outcomes in chronic
population-based characterization of heart failure with mid-range heart failure：does the neurohormonal hypothesis apply to mid-